COS Collagen Solutions Plc

TIDMCOS

RNS Number : 5425C

Collagen Solutions PLC

20 October 2020

20 October 2020

Collagen Solutions plc

("Collagen Solutions" or the "Company")

Collagen Solutions Plc Acquired by Rosen's Diversified, Inc.

Collagen Solutions Plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, announces that today Rosen's Diversified, Inc. ("RDI") declared that its offer to acquire Collagen Solutions plc (the "Offer") had become wholly unconditional and as a result, Collagen Solutions will become part of the RDI Group.

RDI is a multi-billion dollar, family-owned and controlled business, headquartered in Minnesota near the Company's U.S. offices. RDI sells a broad range of food, agricultural and scientific products into more than 30 countries, across five continents, and has over 4,500 employees. Collagen Solutions will become part of RDI's life sciences division, which includes Scientific Life Solutions ("SLS"), a supplier of critical components to the bioresearch and biomedical fields.

Jamal Rushdy, CEO of Collagen Solutions said: "We have made tremendous progress in our vision to be the industry's first choice for regenerative biomaterials. We believe that being part of RDI will generate significant growth opportunities and create enhanced value for the benefit of all stakeholders and in particular our employees, customers and suppliers. I am optimistic and excited for the potential for continued momentum and greater opportunity for Collagen Solutions."

Wade Rosen, Director of RDI and Executive Vice President of Corporate Development of SLS said: "Collagen Solutions represents an attractive strategic and cultural fit with SLS and we have been highly impressed by the long-term vision and ethos of the Company. The successful completion of the Offer will now provide a foundation for SLS to become a major tissue provider in North America, leveraging the RDI Group's local porcine and bovine harvest, logistics and distribution capabilities in the United States. Collagen's international presence will also provide a platform for SLS to extend its supply of porcine and bovine tissue into the EMEA and APAC regions."

England & Company, LLC and Goodbody Stockbrokers UC acted, in relation to the Offer, as joint financial advisers to Collagen Solutions. Shepherd and Wedderburn LLP acted as legal adviser to Collagen Solutions.

Strand Hanson and Faegre Drinker acted, in relation to the Offer, as sole financial adviser and legal adviser to RDI, respectively.

Enquiries:

 
  Collagen Solutions Plc                              via Walbrook 
   Jamal Rushdy, CEO 
   Hilary Spence, CFO 
  England & Company LLC                               Tel: +1 (212) 235-0850 
   (Joint Financial Adviser to Collagen Solutions 
   Plc) 
   Craig England 
   Paul Teitelbaum 
  Goodbody Stockbrokers UC                            Tel: +353 (0) 1 667 
   (Rule 3 Adviser and Joint Financial Adviser         0400 
   to Collagen Solutions Plc) 
   Stephen Kane 
   Christopher McAuliffe 
  Cenkos Securities plc                               Tel: +44 (0) 207 
   (Nominated Adviser and Broker to Collagen           397 8900 
   Solutions Plc) 
   Giles Balleny 
   Max Gould 
  Walbrook PR Ltd                                     Tel: +44 (0) 207 
   (Financial PR adviser to Collagen Solutions         933 8780 
   Plc)                                                or collagen@walbrookpr.com 
   Anna Dunphy                                         Mob: +44 (0) 7876 
                                                       741 001 
  Rosen's Diversified, Inc.                           Tel: +1 (612) 406-5181 
   David Krawitz, Director of Strategy, Operations 
   and Sales 
  Strand Hanson Limited                               Tel: +44 (0) 207 
   (Financial Adviser to Rosen's Diversified,          409 3494 
   Inc.) 
   Stuart Faulkner 
   Matthew Chandler 
   James Dance 
   Jack Botros 
 

Important Notice

England & Company LLC, through its wholly owned subsidiary, England Securities, LLC, is acting as joint financial adviser to Collagen and no-one else in connection with the Offer and other matters described in this announcement and will not be responsible to anyone other than Collagen for providing the protections afforded to clients of England & Company LLC nor for providing advice in relation to the Offer, the contents of this announcement or any other matter referred to herein. Neither England & Company LLC nor any of its subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of England & Company LLC in connection with this announcement, any statement contained herein or otherwise.

Goodbody Stockbrokers UC, trading as Goodbody, which is regulated in Ireland by the Central Bank of Ireland and in the UK by the Financial Conduct Authority, is acting as sole Rule 3 adviser and joint financial adviser to Collagen and no-one else in connection with the Offer and other matters described in this announcement and will not be responsible to anyone other than Collagen for providing the protections afforded to clients of Goodbody Stockbrokers UC nor for providing advice in relation to the Offer, the contents of this announcement or any other matter referred to herein. Neither Goodbody Stockbrokers UC nor any of its subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Goodbody Stockbrokers UC in connection with this announcement, any statement contained herein or otherwise.

Cenkos Securities plc, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting exclusively as nominated adviser and broker to Collagen and no-one else in connection with the Offer and other matters described in this announcement and will not be responsible to anyone other than Collagen for providing the protections afforded to clients of Cenkos Securities plc nor for providing advice in relation to the Offer, the contents of this announcement or any other matter referred to herein. Neither Cenkos Securities plc nor any of its subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Cenkos Securities plc in connection with this announcement, any statement contained herein or otherwise.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ACQDGBDGLXBDGGC

(END) Dow Jones Newswires

October 20, 2020 02:03 ET (06:03 GMT)

Collagen Solutions (LSE:COS)
Graphique Historique de l'Action
De Fév 2025 à Mar 2025

Collagen Solutions (LSE:COS)
Graphique Historique de l'Action
De Mar 2024 à Mar 2025